In this study, we show that an ADC targeting CCRL2 exhibits significant anti-leukemic effects in high-risk MDS/AML, including TP53-mutated cells, but has limited toxicity against normal hematopoietic cells. Here, CCRL2 is linked to acute myeloid leukemia.